28356129|t|The effects of probiotic and synbiotic supplementation on metabolic syndrome indices in adults at risk of type 2 diabetes: study protocol for a randomized controlled trial
28356129|a|The incidence of type 2 diabetes, cardiovascular diseases, and obesity has been rising dramatically; however, their pathogenesis is particularly intriguing. Recently, dysbiosis of the intestinal microbiota has emerged as a new candidate that may be linked to metabolic diseases. We hypothesize that selective modulation of the intestinal microbiota by probiotic or synbiotic supplementation may improve metabolic dysfunction and prevent diabetes in prediabetics. In this study, a synthesis and study of synbiotics will be carried out for the first time in Iran. In a randomized triple-blind controlled clinical trial, 120 adults with impaired glucose tolerance based on the inclusion criteria will be selected by a simple random sampling method and will be randomly allocated to 6 months of 6 g/d probiotic, synbiotic or placebo. The fecal abundance of bacteria, blood pressure, height, weight, and waist and hip circumferences will be measured at baseline and following treatment. Also, plasma lipid profiles, HbA1C, fasting plasma glucose, and insulin levels, will be measured and insulin resistance (HOMA-IR) and beta-cell function (HOMA-B) will be calculated at baseline and will be repeated at months 3, 6, 12, and 18. The data will be compared within and between groups using statistical methods. The results of this trial could contribute to the evidence-based clinical guidelines that address gut microbiota manipulation to maximize health benefits in prevention and management of metabolic syndrome in prediabetes. Iranian Registry of Clinical Trials: IRCT201511032321N2. Registered on 27 February 2016.
28356129	4	14	effects of	T080	C1704420
28356129	15	24	probiotic	T007	C0525033
28356129	29	38	synbiotic	T168	C2936470
28356129	39	54	supplementation	T061	C0242296
28356129	58	76	metabolic syndrome	T047	C0524620
28356129	77	84	indices	T078	C0010439
28356129	88	94	adults	T100	C0001675
28356129	98	102	risk	T078	C0035647
28356129	106	121	type 2 diabetes	T047	C0011860
28356129	123	137	study protocol	T170	C1507394
28356129	144	171	randomized controlled trial	T062	C0206035
28356129	176	185	incidence	T081	C0021149
28356129	189	204	type 2 diabetes	T047	C0011860
28356129	206	229	cardiovascular diseases	T047	C0007222
28356129	235	242	obesity	T047	C0028754
28356129	252	258	rising	T169	C0442805
28356129	288	300	pathogenesis	T046	C0699748
28356129	317	327	intriguing	T041	C0543488
28356129	339	348	dysbiosis	T046	C3658208
28356129	356	377	intestinal microbiota	T001	C2985398
28356129	395	398	new	T080	C0205314
28356129	399	408	candidate	T078	C0392360
28356129	431	449	metabolic diseases	T047	C0025517
28356129	499	520	intestinal microbiota	T001	C2985398
28356129	524	533	probiotic	T007	C0525033
28356129	537	546	synbiotic	T168	C2936470
28356129	547	562	supplementation	T061	C0242296
28356129	563	574	may improve	T080	C1272747
28356129	575	596	metabolic dysfunction	T047	C0025517
28356129	601	608	prevent	T080	C0392756
28356129	609	617	diabetes	T047	C0011847
28356129	621	633	prediabetics	T047	C0362046
28356129	643	648	study	T062	C2603343
28356129	652	661	synthesis	T052	C1883254
28356129	666	671	study	T062	C2603343
28356129	675	685	synbiotics	T168	C2936470
28356129	694	701	carried	T052	C0206243
28356129	728	732	Iran	T083	C0022065
28356129	739	788	randomized triple-blind controlled clinical trial	T062	C0206035
28356129	794	800	adults	T100	C0001675
28356129	806	832	impaired glucose tolerance	T047	C0271650
28356129	846	864	inclusion criteria	T080	C1512693
28356129	873	881	selected	T052	C1707391
28356129	894	900	random	T080	C0439605
28356129	901	916	sampling method	T170	C0449370
28356129	929	937	randomly	T080	C0439605
28356129	938	947	allocated	T052	C1706778
28356129	953	959	months	T079	C0439231
28356129	969	978	probiotic	T007	C0525033
28356129	980	989	synbiotic	T168	C2936470
28356129	993	1000	placebo	T122	C1696465
28356129	1006	1011	fecal	T031	C0015733
28356129	1012	1021	abundance	T080	C2346714
28356129	1025	1033	bacteria	T007	C0004611
28356129	1035	1049	blood pressure	T040	C0005823
28356129	1051	1057	height	T032	C0489786
28356129	1059	1065	weight	T032	C0005910
28356129	1071	1076	waist	T201	C0455829
28356129	1081	1099	hip circumferences	T201	C0562350
28356129	1108	1116	measured	T080	C0444706
28356129	1120	1128	baseline	T081	C1442488
28356129	1133	1142	following	T079	C0332282
28356129	1143	1152	treatment	T061	C0087111
28356129	1160	1181	plasma lipid profiles	T059	C0850354
28356129	1183	1188	HbA1C	T116,T123	C0019018
28356129	1190	1212	fasting plasma glucose	T059	C0583513
28356129	1218	1225	insulin	T116,T121,T125	C0021641
28356129	1226	1232	levels	T080	C0441889
28356129	1242	1250	measured	T080	C0444706
28356129	1255	1273	insulin resistance	T059	C4049994
28356129	1275	1282	HOMA-IR	T059	C4049994
28356129	1288	1306	beta-cell function	T059	C4055385
28356129	1308	1314	HOMA-B	T059	C4055385
28356129	1324	1334	calculated	T052	C1441506
28356129	1338	1346	baseline	T081	C1442488
28356129	1359	1367	repeated	T169	C0205341
28356129	1371	1377	months	T079	C0439231
28356129	1400	1404	data	T078	C1511726
28356129	1413	1421	compared	T052	C1707455
28356129	1441	1447	groups	UnknownType	C0681860
28356129	1448	1453	using	T169	C1524063
28356129	1454	1473	statistical methods	T062	C1710191
28356129	1479	1486	results	T169	C1274040
28356129	1495	1500	trial	T062	C0206035
28356129	1507	1517	contribute	T052	C1880177
28356129	1525	1559	evidence-based clinical guidelines	T170	C0282451
28356129	1573	1587	gut microbiota	T001	C2985398
28356129	1588	1600	manipulation	T061	C0087111
28356129	1604	1612	maximize	T169	C0442805
28356129	1613	1628	health benefits	T081	C0086387
28356129	1632	1642	prevention	T061	C0199176
28356129	1647	1657	management	T058	C0376636
28356129	1661	1679	metabolic syndrome	T047	C0524620
28356129	1683	1694	prediabetes	T047	C0362046
28356129	1696	1712	Iranian Registry	T170	C0034975
28356129	1716	1731	Clinical Trials	T062	C0008976
28356129	1733	1751	IRCT201511032321N2	T170	C0282574